Corcept <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Phase 3 Results for Relacorilant in Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Incorporated has announced new data from its pivotal Phase 3 ROSELLA trial evaluating relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The results, presented at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting, demonstrated a progression-free survival benefit, particularly in patients whose disease progressed while on or after taking a PARP inhibitor. Additionally, Corcept reported the expansion of its Phase 2 BELLA trial to three study arms, which will examine the efficacy and safety of relacorilant plus nab-paclitaxel and bevacizumab in platinum-resistant and platinum-sensitive ovarian cancer, as well as relacorilant plus nab-paclitaxel in endometrial cancer. Initial results from the BELLA trial are expected in late 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20251019109551) on October 19, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。